Table 1.
Characteristics of the selected studies included in this meta-analysis
| References | Country | Health status | Study design | Sample size (control/intervention) | Sex | Intervention (name and daily dose) | Trial duration (day) | Biomarker | Age (control/intervention) | Results (intervention group) | Jaded score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Arruda et al. (2013) | Brazil | Sickle cell anemia patients | R/DB/PC | 39/44 | F/M | Vit C/1,400 mg | 90 | CRP | 22/27 | Significant increase | 5 |
| Vit E/800 mg | |||||||||||
| Arruda et al. (2013) | Brazil | Sickle cell anemia patients | R/DB/PC | 39/44 | F/M | Vit C/1,400 mg | 180 | CRP | 22/27 | Significant increase | |
| Vit E/800 mg | |||||||||||
| Barker et al. (2011) | USA | Patient with anterior cruciate ligament injury | R/DB/PC | 9/10 | M | Vit C/1,000 mg | 104 | CRP | 36/32 | No significant effect | 2 |
| Vit E/400 IU | |||||||||||
| Bruunsgaard et al. (2003) | Denmark | Healthy | R/DB/PC | 52/50 | M | Vit C/500 mg | 1,151 | CRP | 59/61 | No significant effect | 2 |
| Vit E/200 mg | |||||||||||
| Peairs and Rankin (2008) | USA | Overweight | R/DB/PC | 8/10 | F/M | Vit C/1,000 mg | 7 | CRP | 29.9/31.6 | Significant decrease | 2 |
| Vit E/800 IU | |||||||||||
| Tahir et al. (2005) | Ireland | Patient with aortic valvular stenosis | R/SB | 20/41 | F/M | Vit C/1,000 mg | 180 | CRP | 70/66 | No significant effect | 2 |
| Vit E/400 IU | |||||||||||
| Ullegaddi et al. (2005) | UK | Acute ischaemic | R/SB | 24/24 | F/M | Vit C/500 mg | 7 | CRP | 79/76 | Significant decrease | 3 |
| Stroke patients within 12 h of symptom onset | Vit E/800 IU | ||||||||||
| Ullegaddi et al. (2005) | UK | Acute ischaemic | R/SB | 24/24 | F/M | Vit C/500 mg | 14 | CRP | 79/76 | Significant decrease | 3 |
| Stroke patients within 12 h of symptom onset | Vit E/800 IU | ||||||||||
| Ullegaddi et al. (2005) | UK | Acute ischaemic | R/SB | 24/24 | F/M | Vit C/500 mg | 90 | CRP | 79/76 | Significant decrease | 3 |
| Stroke patients within 12 h of symptom onset | Vit E/800 IU | ||||||||||
| Osman et al. (2016) | Malaysia | Hyper-cholesterolemic patients | R/DB/PC | 19/19 | F/M | Vit C/500 mg | 360 | CRP | 41.3/42 | No significant effect | 2 |
| Vit E/80 mg | |||||||||||
| Bloomer et al. (2007) | USA | Healthy persons (without prior exercise) | R/DB/PC | 8/7 | M | Vit C/1,000 mg | 14 | CRP | 25/23 | No significant effect | 3 |
| Mixed tocopherol/378 mg | |||||||||||
| Mixed tocotrinols/39.5 mg | |||||||||||
| Bloomer et al. (2007) | USA | Healthy persons (without prior exercise) | R/DB/PC | 8/7 | M | Vit C/1,000 mg | 15 | CRP | 25/23 | No significant effect | 3 |
| Mixed tocopherol/378 mg | |||||||||||
| Mixed tocotrinols/39.5 mg | |||||||||||
| Bloomer et al. (2007) | USA | Healthy persons (without prior exercise) | R/DB/PC | 8/7 | M | Vit C/1,000 mg | 16 | CRP | 25/23 | No significant effect | 3 |
| Mixed tocopherol/378 mg | |||||||||||
| Mixed tocotrinols/39.5 mg | |||||||||||
| Bloomer et al. (2007) | USA | Healthy persons (with prior exercise) | R/DB/PC | 7/8 | M | Vit C/1,000 mg | 14 | CRP | 22/22 | No significant effect | 3 |
| Mixed tocopherol/378 mg | |||||||||||
| Mixed tocotrinols/39.5 mg | |||||||||||
| Bloomer et al. (2007) | USA | Healthy persons (with prior exercise) | R/DB/PC | 7/8 | M | Vit C/1,000 mg | 15 | CRP | 22/22 | No significant effect | 3 |
| Mixed tocopherol/378 mg | |||||||||||
| Mixed tocotrinols/39.5 mg | |||||||||||
| Bloomer et al. (2007) | USA | Healthy persons (with prior exercise) | R/DB/PC | 7/8 | M | Vit C/1,000 mg | 16 | CRP | 22/22 | No significant effect | 3 |
| Mixed tocopherol/378 mg | |||||||||||
| Mixed tocotrinols/39.5 mg |
DB, double-blinded; SB, single-blinded; PC, placebo-controlled; R, randomized; F, female; M, male.